Core Viewpoint - Barrick Gold Corporation has agreed to sell its 50 percent interest in the Donlin Gold Project for $1 billion in cash, allowing the company to optimize its asset portfolio and focus on long-term sustainable operations [1][4]. Group 1: Transaction Details - The sale involves Paulson Advisers LLC acquiring 80 percent and NOVAGOLD Resources Inc. acquiring 20 percent of Barrick's subsidiary's interest in Donlin Gold LLC [2]. - Barrick has granted NOVAGOLD an option to purchase the outstanding debt related to the Donlin Gold Project for $90 million if purchased before closing, or $100 million within 18 months after closing [1]. Group 2: Financial Implications - Proceeds from the sale will be utilized to strengthen Barrick's balance sheet, invest in future projects, and support shareholder returns [3]. - The transaction is expected to be completed in late Q2 or early Q3 of 2025, subject to customary closing conditions and regulatory approvals [5]. Group 3: Strategic Focus - Barrick's president emphasized the strategic decision to exit the Donlin Gold Project at an attractive valuation, allowing NOVAGOLD and Paulson to develop the project while Barrick focuses on its priority growth projects [4].

Core Insights - StoneX Group Inc. has received approval from CME Group to operate a New York vault for storing and delivering precious metals, enhancing its integrated offerings in this sector [1][2][3] Group 1: Approval and Infrastructure - The approval allows StoneX clients to access the COMEX and NYMEX delivery network through the New York vault, facilitating secure storage and direct exchange access for institutional traders and other clients [2][3] - The New York vault is one of only 11 depositories in the U.S. approved for COMEX and NYMEX deliveries, positioning it as a key logistical hub for exchange-traded metals [3] Group 2: Market Context and Demand - There has been a record influx of physical metal into New York, with COMEX inventories exceeding 43 million ounces of gold in Q1 2025, indicating strong global demand for U.S.-based storage solutions [2] - The establishment of the New York vault enhances market infrastructure and expands delivery options for clients, reinforcing StoneX's capabilities in physical metals logistics [2][3] Group 3: Strategic Vision and Leadership - The approval aligns with StoneX's long-term strategy to create a fully integrated global metals platform, enhancing its ability to serve clients from trade execution to physical settlement [4] - Leadership emphasizes the significance of this development in providing seamless, end-to-end solutions for precious metals clients, highlighting the firm's unique position as both a regulated FCM and an exchange-approved depository [4]

Singapore, April 22, 2025 (GLOBE NEWSWIRE) -- Concorde International Group Ltd. (NASDAQ: CIGL) (“Concorde” or the “Company”), an integrated security services provider that combines physical manpower and innovative technology to deliver effective security solutions, today announced the pricing of its initial public offering (the "Offering") of 1,250,000 Class A ordinary shares (the "Class A Ordinary Shares") at a public offering price of US$4.00 per share. The Class A Ordinary Shares have been approved for l ...

MONTVALE, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today published its 2024 Sustainability Report. Our Sustainability Report outlines the Company's ongoing commitment to providing employees, customers, shareholders, and the communities in which we operate with information on Balchem's sustainability initiatives, guided by our core values and our vision of making the world a healthier place. “I am pleased with the progress Balchem continues to make in advancing our broad-ba ...

Gwinnett County road network made safer with smart corridorKapsch TrafficCom is providing its complete Connected Vehicle (CV) portfolioCounty-wide project creates model for easier CV deployment in neighboring counties DULUTH, Ga., April 22, 2025 (GLOBE NEWSWIRE) -- Kapsch TrafficCom has completed deployment and transitioned to the operations and maintenance phase of a turnkey smart corridor project covering almost 400 intersections in Gwinnett County, Georgia. As part of this initiative, Kapsch TrafficCom ...

Demonstrates continuous growth through ongoing re-orders from Tier-1 manufacturers Customer’s drones are gaining strong traction with U.S. Department of Defense (DoD) and other defense purchasers Palo Alto, California, April 22, 2025 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB), a provider of cybersecurity and robust solutions for drones and robotics, today announced receipt of its latest, the sixth, commercial scale follow-on order for its SkyHopper PRO datalinks from one of the largest U.S. drone ...

TORONTO and HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto on May 5-6, 2025. Details on the prese ...

Core Viewpoint - ECARX Holdings Inc. has announced a strategic partnership with HERE Technologies to co-develop an AI-powered in-vehicle navigation system aimed at global automakers, set to debut at Auto Shanghai 2025 [1][2][4] Company Overview - ECARX is a global automotive technology provider specializing in full-stack solutions for next-generation smart vehicles, including system on a chip (SoC) and central computing platforms [5] - Founded in 2017 and listed on Nasdaq in 2022, ECARX employs over 1,900 people across 12 major locations worldwide [6] - The company has partnerships with notable automakers such as Volkswagen Group, FAW, and Dongfeng Peugeot-Citroën, with its products present in over 8.1 million vehicles globally [6] Partnership Details - The collaboration combines HERE's advanced navigation platform with ECARX's full-stack solutions to create a navigation system that meets the evolving needs of automakers [2][4] - The new navigation system is designed for multi-scenario adaptability, high data accuracy, and robust technical performance, supporting high-precision mapping and real-time navigation [3][4] Technical Features - The jointly developed navigation system will utilize HERE's SDK and global location data, allowing automakers to reduce development cycles and ensure compliance with international data regulations [2][4] - The system aims to provide a plug-and-play global navigation development framework for automakers, facilitating faster market entry for new navigation solutions [4]

Core Viewpoint - Autolus Therapeutics plc is set to release its first quarter 2025 financial results and operational highlights on May 8, 2025, before the US markets open [1]. Group 1: Financial Results Announcement - The company will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss the financial results and provide a general business update [2]. - Participants are required to pre-register to receive dial-in numbers and a personal PIN for accessing the conference call [2]. Group 2: Company Overview - Autolus Therapeutics plc is an early commercial stage biopharmaceutical company focused on developing next-generation T cell therapies for cancer and autoimmune diseases [3]. - The company utilizes proprietary and modular T cell programming technologies to create targeted and highly active T cell therapies [3]. - Autolus has an FDA-approved product, AUCATZYL, and a pipeline of candidates for treating hematological malignancies, solid tumors, and autoimmune diseases [3].

Core Insights - Kymera Therapeutics has initiated dosing in the BroADen Phase 1b clinical trial for KT-621, targeting moderate to severe atopic dermatitis (AD), with data expected in Q4 2025 [1][2] - The company has completed the SAD/MAD dosing in the KT-621 Phase 1 healthy volunteer trial, with results anticipated in June 2025 [1] - Two parallel Phase 2b trials for KT-621 in AD and asthma are planned to commence in Q4 2025 and Q1 2026, respectively [3] Company Overview - Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases [1][8] - The company aims to revolutionize treatment for complex immuno-inflammatory diseases through its unique technology, which offers biologics-like profiles in an oral format [2][4] - KT-621 is the first STAT6-targeted agent in clinical development, with the potential to significantly alleviate the burden of AD through effective oral administration [2][4] Clinical Trial Details - The BroADen Phase 1b trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of KT-621 in approximately 20 adult patients with moderate to severe AD [2] - The primary objective is to demonstrate robust STAT6 degradation and its effects on Th2 biomarkers, alongside clinical endpoints like the Eczema Area and Severity Index (EASI) [2] - The upcoming Phase 2b trials are designed to accelerate the development of KT-621 and facilitate dose selection for subsequent Phase 3 studies across various Th2-related conditions [3] Product Information - KT-621 is a first-in-class, once-daily oral degrader of STAT6, which is crucial for IL-4/IL-13 signaling and Th2 inflammation [4] - Preclinical studies have shown that KT-621 exhibits dupilumab-like activity, indicating its potential effectiveness in treating Th2 diseases [4] - The drug aims to provide a more convenient treatment option compared to injectable biologics, potentially reaching a broader patient population [4][6] Market Context - Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition that significantly impacts patients' quality of life, with a notable unmet need for improved treatment options [6] - Current treatments include topical therapies and injectable biologics, but there remains a significant opportunity for new oral therapies like KT-621 to address this need [6]